Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 88, Issue 10, 2017, Pages 811-817

  Hyun, Jae Won ^a   Woodhall, Mark R ^b   Kim, Su Hyun ^a   Jeong, In Hye ^a   Kong, Byungsoo ^a   Kim, Gayoung ^a   Kim, Yeseul ^a   Park, Min Su ^c   Irani, Sarosh R ^b   Waters, Patrick ^b   Kim, Ho Jin ^a  

^a National Cancer Control Institute   (South Korea)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; IMMUNOGLOBULIN G; MITOXANTRONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; PROTEIN ANTIBODY; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; AUTOANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ADOLESCENT; ADULT; ARTICLE; CELL ASSAY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; PHENOTYPE; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SCHOOL CHILD; SEROLOGY; SEROPREVALENCE; BLOOD; IMMUNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; SEROEPIDEMIOLOGY;

AQUAPORIN 4; AUTOANTIBODIES; DEMYELINATING AUTOIMMUNE DISEASES, CNS; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; SEROEPIDEMIOLOGIC STUDIES;

EID: 85030446793     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2017-315998     Document Type: Article

References (35)

1. Schluesener HJ, Sobel RA, Linington C, et al. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987;139:4016-21.
2. Brunner C, Lassmann H, Waehneldt TV, et al. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2', 3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. J Neurochem 1989;52:296-304.
3. Linington C, Bradl M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-54.
4. Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 2016;15:307-24.
5. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015;2:e62.
6. Reindl M, Di Pauli, F, Rostásy K, et al. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013;9:455-61.
7. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in Neuromyelitis optica and related disorders. J Neuroinflammation 2011;8:184.
8. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-7.
9. Rostásy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013;19:1052-9.
10. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibodypositive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-81.
11. Tanaka M, Tanaka K. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol 2014;270:98-9.
12. H öftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015;21:866-74.
13. Pröbstel AK, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 2015;12:46.
14. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016;13:279.
15. Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011;138:247-54.
16. Pröbstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011;77:580-8.
17. Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015;86:265-72.
18. Dale RC, Tantsis EM, Merheb V, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 2014;1:e12.
19. Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2014;1:e40.
20. Cobo-Calvo Á, Sepúlveda M, Bernard-Valnet R, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. Mult Scler 2016;22:312-9.
21. Di Pauli F, Höftberger R, Reindl M, et al. Fulminant demyelinating encephalomyelitis. Neurol Neuroimmunology Neuroinflammation 2015;2:e175.
22. Lechner C, Baumann M, Hennes EM, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 2016;87:897-905.
23. Baumann M, Hennes EM, Schanda K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases. Mult Scler 2016;22:1821-9.
24. Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016;3:e257.
25. Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015;2:e163.
26. Fujimori J, Takai Y, Nakashima I, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry 2017;88:534-6.
27. Reindl M, Jarius S, Rostasy K, et al. Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol 2017;30:295-301.
28. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.
29. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
30. Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e89.
31. Kim Y, Kim G, Kong BS, et al. Large scale in-house cell based assay for the evaluation of serostatus in patients with neuromyelitis optica spectrum disorder based on new diagnostic criteria. J Clin Neurol 2017;13:175-80.
32. Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010;291:52-6.
33. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-71.
34. Ikeda K, Kiyota N, Kuroda H, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler 2015;21:656-9.
35. Kaneko K, Sato DK, Nakashima I, et al. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry 2016;87:1257-9.